Brazilian pharmaceutical industry and generic drugs policy: Impacts on structure and innovation and recent developments

Caliari, Thiago; Ruiz, Ricardo Machado

doi:10.1093/scipol/sct053

Cited by 19 publications

(22 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Podemos extrair algumas características principais da indústria farmacêutica que se procurará explicar pelo modelo History-friendly 4 a ser desenvolvido nesse capítulo: 1) A estratégia de produção de medicamentos genéricos tem sinalizado ser uma estratégia importante na geração de receita e incremento de mercado Ruiz, 2013); 2) A relevância da estratégia de inovação incremental realizada pelas empresas (Gilbert, Henske;Ashish, 2003;Love, 2003;Ganuza et al, 2009); 3) As estratégias de marketing têm sido utilizadas com frequência pela indústria farmacêutica, principalmente pelas grandes empresas inovadoras, na tentativa de diferenciar seus produtos de referência devido à concorrência de mercado com a expiração de patentes e a consequente entrada de empresas fabricantes de medicamentos genéricos (Angell, 2004;Gagnon;Lexchin, 2008).…”

Section: Modelo Evolucionário Para a Indústria Farmacêuticaunclassified

“…Em linhas gerais, a estrutura de definição do modelo seguirá as especificações apresentadas nos tópicos abaixo: 1) A oferta é fixa e definida por firmas inovadoras, firmas imitadoras e firmas competitivas Ruiz, 2013): as firmas inovadoras e imitadoras realizarão P&D e poderão inserir produtos inovadores no mercado e as empresas competitivas serão especializadas na produção de medicamentos genéricos. Existem três (3) firmas de cada tipo, sendo a numeração destas estabelecida da menos inovadora para a mais inovadora.…”

Section: Características Fundamentaisunclassified

See 1 more Smart Citation

Apropriabilidade tecnológica e preferências da demanda: o caso da indústria farmacêutica*

2018

View full text Add to dashboard Cite

ResumoO artigo desenvolve um modelo evolucionário History-friendly para a indústria farmacêutica, com replicações de características específicas ao mercado brasileiro. O ponto de enfoque dessa estratégia de análise foi demonstrar a relevância que diferentes especificações da demanda têm sobre os resultados econômicos e tecnológicos em indústrias com elevado grau de desenvolvimento tecnológico, nos moldes das questões levantadas por Nelson (2013). Em suma, os resultados destacam a importância da consideração da demanda nos modelos evolucionários e são conclusivos nesse objetivo. Mudanças consideráveis nos resultados de mercado, financeiros e tecnológicos de firmas industriais foram alcançadas com modificações na parametrização dos consumidores.Palavras-chave: Indústria farmacêutica; Modelo evolucionário; Heterogeneidade da demanda; Inovação; Medicamentos genéricos. Abstract Technological appropriability and demand preferences: the case of the pharmaceutical industryThis paper develops a history-friendly model for the pharmaceutical industry, with replications of features specific to the Brazilian market. The goal was to demonstrate the relevance of demand on the economic and technological progress in industries with high technological development, as pointed out by Nelson (2013). In short, the findings highlight the importance of considering the demand heterogeneity in evolutionary models and are conclusive regarding this objective. Significant changes in the market, financial and technological results for industrial firms were achieved with changes to the parameterization of consumers.

show abstract

Section: Modelo Evolucionário Para a Indústria Farmacêuticaunclassified

Section: Características Fundamentaisunclassified

Apropriabilidade tecnológica e preferências da demanda: o caso da indústria farmacêutica*

2018

View full text Add to dashboard Cite

show abstract

“…Other policies also worked against them: changes in the rules of public procurement in the 1990s that prioritised price meant that drug procurement pushed many local companies out of this important section of the market. As a result, only one among the top 20 pharmaceutical companies in Brazil during the mid-1990s was nationally owned (Caliari and Ruiz, 2014).…”

mentioning

confidence: 99%

“…Offering an example of what could be achieved by co-articulated policies, as a result of this and other policies (e.g. procurement and tax incentives), the share of generics markets in Brazil grew to 17-18% of the total market at the end of the decade, of which nearly 90% was controlled by Brazilian firms (Gadelha et al 2013;Caliari & Ruiz 2014).…”

mentioning

confidence: 99%

“…Whether this will lead to genuine innovative capacities within the domestic sector remains to be seen; data suggest that GFB members have increased their R&D intensity, although it remains low by international standards (GFB, 2014). Another factor that may hinder the entry of Brazilian pharmaceutical companies into the patent game is the ever-present risk of being acquired by foreign proprietary companies; in the absence of controls over foreign ownership in the health-pharmaceutical sector, some emerging domestic companies have already been acquired by foreign companies (Caliari and Ruiz, 2014;Viana and Silva, 2015).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Interrupted Constructions: The Brazilian Health-Industrial Complex in Historical Perspective

Muzaka¹

2018

Latin American Perspectives

View full text Add to dashboard Cite

Officially launched in 2007, Brazil's Health-Industrial Silva, 2004 Calls to resume interrupted constructions are not rare in Brazil, nor is it surprising that President Lula should want to make political capital of Furtado's vision for Brazil while commemorating his death. Regardless of what Lula himself made of Furtado's ideas, amidst the uneasy mix of hopes and disillusionment that accompanied his two terms in office (2003-10), a self-proclaimed Furtadian project was indeed in the making: constructing a health-industrial complex in Brazil. Seeking to co-articulate the logic of building a dynamic industrial base, and the logic of providing universal and egalitarian healthcare, the health-industrial complex proposed itself as a means of addressing social inequality, dependency on foreign technology, and weaknesses in the national innovation and productive systems simultaneously, with the ultimate purpose that of helping propel Brazil's socio-economic development forward (Gadelha et al., 2003; Gadelha, 2006). The project of building a Brazilian health-industrial complex was promptly embraced by the Lula administration.

show abstract

The Brazilian Experience with Excessive Pricing Cases: Hello, Goodbye

Ribeiro

Mattos

2018

Excessive Pricing and Competition Law Enforcement

View full text Add to dashboard Cite

Brazilian pharmaceutical industry and generic drugs policy: Impacts on structure and innovation and recent developments

Cited by 19 publications

References 10 publications

Apropriabilidade tecnológica e preferências da demanda: o caso da indústria farmacêutica*

Apropriabilidade tecnológica e preferências da demanda: o caso da indústria farmacêutica*

Interrupted Constructions: The Brazilian Health-Industrial Complex in Historical Perspective

The Brazilian Experience with Excessive Pricing Cases: Hello, Goodbye

Contact Info

Product

Resources

About